Isofol Medical AB (ISOFOL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Isofol Medical AB (ISOFOL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8055
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Isofol Medical AB (Isofol) is a clinical stage pharmaceutical company that develops folate-based therapies for the treatment of cancer patients. The company offers clinical lead candidate Modufolin, a novel folate-based therapy, which is developed to increase the efficacy and reduce the side effects of antimetabolites used in cancer treatment. It offers active pharmaceutical ingredient (API) of arfolitixorin, which is the key active metabolite of all clinically used folate-based drugs including leucovorin and levoleucovorin. Isofol offers HDMTX rescue therapy with arfolitixorin, which is a common therapeutic regimen in the treatment of osteosarcoma. The company also offers research and development services. Isofol is headquartered in Gothenburg, Sweden.

Isofol Medical AB (ISOFOL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Isofol Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Isofol Medical AB, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Isofol Medical Raises USD1.2 Million in Venture Financing 11
Licensing Agreements 12
Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 12
Equity Offering 13
Isofol Medical Raises USD48.6 Million in IPO 13
Isofol Medical Raises USD4.7 Million in Public Offering of Shares 14
Isofol Medical AB – Key Competitors 15
Isofol Medical AB – Key Employees 16
Isofol Medical AB – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Financial Announcements 18
Nov 20, 2017: Isofol Medical: Interim Report January – September 2017 18
Aug 21, 2017: Isofol Medical: Interim Report 2017 (January 2017 – June 2017) 20
Mar 20, 2017: Isofol’s Year-End Report January – December 2016 22
Corporate Communications 24
Sep 11, 2018: New Chairman and extended board at Isofol Medical 24
Product News 25
11/27/2017: Isofol announces that an abstract regarding Modufolins efficacy in colorectal cancer treatment will be presented at ASCO-GI 2018 25
10/03/2017: Isofol appoints Gustaf Albert as Chief Financial Officer 26
09/11/2017: Isofol announces that Modufolin as a rescue therapy in the treatment of osteosarcoma in children is safe and preventive of HDMTX toxicities 27
08/24/2017: From the ongoing ISO-CC-005 study, Isofol reports initial indications of efficacy of Modufolin in patients with metastatic colorectal cancer 28
08/18/2017: Isofols appoints Sven Erickson as Chief Commercial Officer 29
08/16/2017: Isofol establish cooperation with Prof. Sten Nilsson and Dr. Alain Herrera in preparation for the upcoming pivotal trial with Modufolin 30
07/03/2017: New scientific findings strengthen rationale and motivation for Isofol Medical to conduct the pivotal ISO-CC-007 study 31
06/21/2017: Isofol has initiated five additional study sites in the ISO-CC-005 study in which Modufolin is evaluated in colorectal cancer 32
05/22/2017: Isofol Announces Publication of an Abstract for the 2017 ASCO Annual Meeting 33
05/03/2017: Isofol Accepted for Presentation of Abstract at the 2017 ASCO Annual Meeting 34
04/11/2017: Isofol has successfully completed the ISO-MTX-003 study in which Modufolin is evaluated as rescue therapy 35
02/08/2018: Isofol reports successful outcome from the scientific advice with the EMA 36
01/18/2018: Positive treatment results with Modufolin (arfolitixorin) will be published at a cancer congress in the US 37
01/11/2018: Isofol Announces Positive Efficacy Data For Modufolin (Arfolitixorin) In Patients Treated For Metastatic Colorectal Cancer 38
Product Approvals 39
Sep 04, 2017: Isofol Medical announces successful Type C meeting with FDA regarding its drug candidate, Modufolin for treatment of metastatic colorectal cancer 39
Clinical Trials 40
Feb 19, 2018: Isofol Medical adopts the World Health Organization recommended name (INN) arfolitixorin for Modufolin 40
Jan 17, 2018: Successful End-of-Phase 2 meeting with FDA and Phase 3 Program for Modufolin agreed 41
Jul 24, 2017: Isofol Announces that an Abstract about Modufolin in Osteosarcoma Treatment will be Presented at ESMO 2017 42
Jul 05, 2017: Isofol Has Enrolled And Dosed Its First Group Of Patients In The Ind-study Iso-ff-001 43
Jan 24, 2017: FDA Clears Isofol’S IND Application To Start Clinical Program Within Colorectal Cancer With Modufolin 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Isofol Medical AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Isofol Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Isofol Medical AB, Deals By Therapy Area, 2012 to YTD 2018 9
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Isofol Medical Raises USD1.2 Million in Venture Financing 11
Isofol Medical Enters Into Licensing Agreement With Merck For Modufolin 12
Isofol Medical Raises USD48.6 Million in IPO 13
Isofol Medical Raises USD4.7 Million in Public Offering of Shares 14
Isofol Medical AB, Key Competitors 15
Isofol Medical AB, Key Employees 16

List of Figures
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Isofol Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Isofol Medical AB (ISOFOL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Abzena Plc (ABZA)-製薬・医療分野:企業M&A・提携分析
    Summary Abzena Plc (Abzena), formerly Polytherics Group Ltd is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company's technologies include a …
  • Public Broadcasting Service:企業の戦略的SWOT分析
    Public Broadcasting Service - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Ambrx Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Ambrx Inc (Ambrx) is a biopharmaceutical company that offers discovery and development of protein-based medicines by using its expanded genetic code. The company provides pipeline product candidate’s portfolio such as ARX618 FGF21, PSMA ADC, CD70 ADC and Anti-CD3 X Folate. It develops pipeli …
  • Zucara Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Zucara Therapeutics Inc (Zucara Therapeutics) is a pharmaceutical company that develops novel drug therapies to prevent hypoglycemia in people with diabetes. The company’s technology is used to prevent the dangerous low blood sugar by restoring the body’s ability to counter-regulate hypoglyc …
  • Deutsche Bank AG:企業のM&A・事業提携・投資動向
    Deutsche Bank AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Deutsche Bank AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Sigmatech, Inc.:企業の戦略・SWOT・財務情報
    Sigmatech, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sigmatech, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Crossject SA (ALCJ):企業の財務・戦略的SWOT分析
    Summary Crossject SA (Crossject) is a medical device company that develops injection systems. The company’s pipeline products include sumatriptan for the treatment of migraines and cluster headaches; adrenaline for the treatment of anaphylactic shock; hydrocortisone for the treatment of acute adrena …
  • Apple Inc:企業のM&A・事業提携・投資動向
    Apple Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Apple Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • ACB Securities Co Ltd:企業の戦略的SWOT分析
    ACB Securities Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Abengoa, S.A.:企業の戦略・SWOT・財務情報
    Abengoa, S.A. - Strategy, SWOT and Corporate Finance Report Summary Abengoa, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • KSK Energy Ventures Ltd (KSK):企業の財務・戦略的SWOT分析
    KSK Energy Ventures Ltd (KSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Perseus Mining Limited:企業の戦略・SWOT・財務情報
    Perseus Mining Limited - Strategy, SWOT and Corporate Finance Report Summary Perseus Mining Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Incitec Pivot Ltd (IPL):企業の財務・戦略的SWOT分析
    Incitec Pivot Ltd (IPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Sociedad Minera El Brocal SAA (BROCALC1):企業の財務・戦略的SWOT分析
    Sociedad Minera El Brocal SAA (BROCALC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Eastman Chemical Company:企業のM&A・事業提携・投資動向
    Eastman Chemical Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Eastman Chemical Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Universal Display Corp (OLED):企業の財務・戦略的SWOT分析
    Summary Universal Display Corp (UDC) is a clean technology company that conducts research, develops and markets organic light emitting diode, technologies and materials. The company offers PHOLED materials which are used in making OLED displays and lighting panels. It provides technologies such as F …
  • Invion Ltd (IVX)-製薬・医療分野:企業M&A・提携分析
    Summary Invion Ltd (Invion) is a life sciences company that develops products for the treatment of inflammatory diseases such as chronic inflammatory, airway disease and inflammation caused by autoimmune disease. The company's pipeline products include INV102 nadolol, a beta blocker for inflammatory …
  • Japan Petroleum Exploration Co Ltd (1662):石油・ガス:M&Aディール及び事業提携情報
    Summary Japan Petroleum Exploration Co Ltd (JAPEX) is an oil and gas company that offers exploration, development, production, and sales of oil, natural gas, and other energy resources. The company’s services include acquisition of blocks, development, exploration, supplying, selling, and transporta …
  • Telephonics Corp:企業の戦略的SWOT分析
    Telephonics Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Noront Resources Ltd:企業のM&A・事業提携・投資動向
    Noront Resources Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Noront Resources Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆